Prostatic Diseases: Clinical Trials

605 trials for Prostatic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

605 completed. 605 Phase 1, 175 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1605Completed 605
Phase 2175Completed 175

Follow Prostatic Diseases: new trials by email Literature Review of Prostatic Diseases trials Research Report on Prostatic Diseases

Trials (filtered) newest first · largest first

All 605 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer
[68Ga]Ga-OncoACP3 - Prostate Cancer
Phase 1CompletedPhilogen S.p.A.202026-05-272026-10-27
A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846
CKD-846, D091 - Benign Prostate Hypertrophy(BPH)
Phase 1CompletedChong Kun Dang Pharmaceutical342026-02-232026-07-21
A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers
AD-116, AD-1161 - Benign Prostatic Hyperplasia
Phase 1CompletedAddpharma Inc.442026-01-222026-07-28
BOTOX Injection Technique for LUTS Due to BPH
Botulinum Toxin Type A (BoNT-A) - Benign Prostatic Hyperplasia
Phase 1CompletedBenha University602025-10-012026-06-12
A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects
HRS-5041 Tablets, Rifampicin Capsule - Prostate Cancer
Phase 1CompletedJiangsu HengRui Medicine Co., Ltd.162025-06-202025-09-10
A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults
Flotufolastat F-18 Injection - Prostate Cancer
Phase 1CompletedSinotau Pharmaceutical Group62025-06-072026-11-10
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer
[68Ga]Ga-OncoACP3 - Prostate Cancer, Prostate Cancer Metastatic Disease
Phase 1CompletedPhilogen S.p.A.202025-04-082026-01-06
Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial
Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio), Lidocaine, Biopsy of Prostate - Prostate Cancer
Phase 1 / Phase 2CompletedUniversity of Washington3502025-01-092026-02-17
Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane Antigen
One single intravenous injection of [177Lu]Lu-BQ7876 - Prostate Cancers
Phase 1CompletedTomsk National Research Medical Center of the Russian Academy of Sciences72024-10-012026-06-26
Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants
HRS-5041 dose level 1, HRS-5041 dose level 2 - Prostate Cancer
Phase 1CompletedAtridia Pty Ltd.242024-09-252025-03-18
A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)
[¹⁴C]Opevesostat, Prednisone, Fludrocortisone - Metastatic Prostate Cancer
Phase 1CompletedMerck Sharp & Dohme LLC82024-09-192024-10-23
A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)
MK-5684, Prednisone, Fludrocortisone acetate - Prostatic Neoplasms
Phase 1CompletedMerck Sharp & Dohme LLC122024-07-112024-10-15
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
APL-5125 - Colorectal Cancer, Cholangiocarcinoma
Phase 1CompletedApollo Therapeutics Ltd272024-06-182026-10-05
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients
68Ga-NYM032 injection - Prostate Cancer
Phase 1 / Phase 2CompletedNorroy Bioscience Co., LTD202024-06-042025-05-21
Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy
NeuroSAFE procedure, LaserSAFE procedure - Prostate Cancer
Phase 1 / Phase 2CompletedUniversity College, London212024-05-152025-01-10
A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
Opevesostat, Dexamethasone, Fludrocortisone - Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
Phase 1CompletedMerck Sharp & Dohme LLC142024-01-302026-03-19
A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
Opevesostat, Dexamethasone, Fludrocortisone acetate - Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
Phase 1CompletedMerck Sharp & Dohme LLC72023-11-142026-04-27
A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846
CKD-846, D091 - Benign Prostate Hypertrophy(BPH)
Phase 1CompletedChong Kun Dang Pharmaceutical312023-11-132026-01-14
Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413
Whole body study and SPECT with [99mTc]Tc-BQ0413 - Prostate Cancer
Phase 1CompletedTomsk National Research Medical Center of the Russian Academy of Sciences102023-10-192026-06-24
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
Saruparib (AZD5305), Darolutamide, No Treatment - Prostate Cancer
Phase 1CompletedAstraZeneca1132023-09-212026-06-30

Showing 20 of 605. Sign in to see all of them.

Narrower conditions

Prostatic Neoplasms (552)  ·  Breast Neoplasms (91)  ·  Neoplasms (70)  ·  Carcinoma, Non-Small-Cell Lung (53)  ·  Ovarian Neoplasms (53)  ·  Prostatic Hyperplasia (48)  ·  Pancreatic Neoplasms (46)  ·  Urinary Bladder Neoplasms (45)  ·  Colorectal Neoplasms (40)  ·  Lung Neoplasms (39)  ·  Melanoma (35)  ·  Colonic Neoplasms (34)  ·  Neoplasm Metastasis (33)  ·  Esophageal Neoplasms (32)  ·  Head and Neck Neoplasms (31)

Broader conditions

Urogenital Diseases (605)  ·  Genital Diseases (604)  ·  Male Urogenital Diseases (604)  ·  Genital Diseases, Male (601)  ·  Neoplasms by Site (554)  ·  Genital Neoplasms, Male (553)  ·  Urogenital Neoplasms (551)  ·  Neoplasms (487)  ·  Female Urogenital Diseases (106)  ·  Female Urogenital Diseases and Pregnancy Complications (106)  ·  Skin and Connective Tissue Diseases (106)  ·  Skin Diseases (105)  ·  Breast Diseases (97)  ·  Neoplasms by Histologic Type (91)

Interventions

Docetaxel (42)  ·  Prednisone (27)  ·  enzalutamide (21)  ·  Abiraterone Acetate (18)  ·  Radiotherapy (16)  ·  Tamsulosin (14)  ·  bicalutamide (13)  ·  Dutasteride (12)  ·  Goserelin (12)  ·  Leuprolide (10)  ·  Estramustine (8)  ·  Paclitaxel (8)  ·  abiraterone (8)  ·  pembrolizumab (8)  ·  Radiotherapy, Intensity-Modulated (7)

Sponsors

National Cancer Institute (NCI) (41)  ·  Memorial Sloan Kettering Cancer Center (32)  ·  GlaxoSmithKline (14)  ·  M.D. Anderson Cancer Center (12)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (11)  ·  AstraZeneca (10)  ·  Janssen Research & Development, LLC (10)  ·  Weill Medical College of Cornell University (9)  ·  University Health Network, Toronto (8)  ·  Bayer (7)  ·  Millennium Pharmaceuticals, Inc. (7)  ·  Pfizer (7)  ·  Chong Kun Dang Pharmaceutical (6)  ·  Merck Sharp & Dohme LLC (6)  ·  Molecular Insight Pharmaceuticals, Inc. (6)

Countries

United States (417)  ·  Canada (44)  ·  United Kingdom (38)  ·  South Korea (25)  ·  Australia (17)  ·  Spain (15)  ·  Netherlands (14)  ·  France (13)  ·  China (12)  ·  Germany (12)  ·  Belgium (11)  ·  Denmark (11)  ·  Japan (10)  ·  Italy (9)  ·  Russia (7)

Top investigators

Michael Morris, MD (6)  ·  Susan Slovin, MD, PhD (6)  ·  James L Gulley, M.D. (5)  ·  Scott Tagawa, MD (4)  ·  Howard I. Scher, MD (3)  ·  Keith A. Rodvold (3)

Results publications

PMID 33465252, PMID 36383907, PMID 19949018, PMID 22002018, PMID 22747660, PMID 25475068, PMID 28800206, PMID 37496366, PMID 41044356, PMID 10661346, PMID 11828001, PMID 12694838, PMID 14504052, PMID 14529764, PMID 14967428, PMID 15590164, PMID 15671557, PMID 15735119, PMID 15936549, PMID 16145049, PMID 16597660, PMID 17707059, PMID 17920349, PMID 18245546, PMID 18384719, PMID 18464023, PMID 18523152, PMID 19192962, PMID 19349545, PMID 19375217, PMID 19499186, PMID 19577865, PMID 19706807, PMID 20068553, PMID 20179219, PMID 20346578, PMID 20398037, PMID 20398925, PMID 20407240, PMID 20501622, PMID 20598811, PMID 20818327, PMID 20824184, PMID 21106711, PMID 21163871, PMID 21377288, PMID 21414514, PMID 21917625, PMID 21976132, PMID 22044694

NIH funding

P30CA008748 (6), 2014 (5), P30CA072720 (4), 2015 (3), 2017 (3), P30CA015083 (3), P30CA016672 (3), P50CA058204 (3), U01CA069856 (3), U01CA069912 (3), P30CA016056 (2), P30CA093373 (2), P30CA124435 (2), R01CA207645 (2), U01CA062505 (2)